PAR1 Participates in the Ability of Multidrug Resistance and Tumorigenesis by Controlling Hippo-YAP Pathway

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Oct 3

PMID 26431277

Citations 25

Authors

Daisuke Fujimoto

Yuki Ueda

Yasuo Hirono

Takanori Goi

Akio Yamaguchi

Affiliations

Soon will be listed here.

Abstract

The Hippo pathway significantly correlates with organ size control and tumorigenesis. The activity of YAP/TAZ, a transducer of the Hippo pathway, is required to sustain self-renewal and tumor-initiation capacities in cancer stem cells (CSCs). But, upstream signals that control the mammalian Hippo pathway have not been well understood. Here, we reveal a connection between the Protease-activated receptor 1 (PAR1) signaling pathway and the Hippo-YAP pathway in gastric cancer stem-like cells. The selective PAR1 agonist TFLLR-NH2 induces an increase in the fraction of side population cells which is enriched in CSCs, and promotes tumorigenesis, multi cancer drug resistance, cell morphological change, and cell invasion which are characteristics of CSCs. In addition, PAR1 activation inhibits the Hippo-YAP pathway kinase Lats via Rho GTPase. Lats kinase inhibition in turn results in increased nuclear localization of dephosphorylated YAP. Furthermore, PAR1 activation confers CSCs related traits via the Hippo-YAP pathway, and the Hippo-YAP pathway correlates with epithelial mesenchymal transition which is induced by PAR1 activation. Our research suggests that the PAR1 signaling deeply participates in the ability of multi drug resistance and tumorigenesis through interactions with the Hippo-YAP pathway signaling in gastric cancer stem-like cells. We presume that inhibited YAP is a new therapeutic target in the treatment human gastric cancer invasion and metastasis by dysregulated PAR1 or its agonists.

Citing Articles

RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential.

Ning Y, Zheng M, Zhang Y, Jiao Y, Wang J, Zhang S Cancer Cell Int. 2024; 24(1):339.

PMID: 39402585 PMC: 11475559. DOI: 10.1186/s12935-024-03519-7.

On the Value of In Vitro Cell Systems for Mechanobiology from the Perspective of Yes-Associated Protein/Transcriptional Co-Activator with a PDZ-Binding Motif and Focal Adhesion Kinase and Their Involvement in Wound Healing, Cancer, Aging, and....

Steinberg T, Dieterle M, Ramminger I, Klein C, Brossette J, Husari A Int J Mol Sci. 2023; 24(16).

PMID: 37628858 PMC: 10454169. DOI: 10.3390/ijms241612677.

An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis.

Yan H, Zhang J, Leung K, Lo K, Yu J, To K Cancers (Basel). 2023; 15(3).

PMID: 36765694 PMC: 9913146. DOI: 10.3390/cancers15030736.

Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression.

Messina B, Lo Sardo F, Scalera S, Memeo L, Colarossi C, Mare M Cell Death Dis. 2023; 14(1):21.

PMID: 36635265 PMC: 9837097. DOI: 10.1038/s41419-023-05568-8.

Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside.

Liu X, Wang Y, Chen B, Chan W, Mui C, Cheung A Biomedicines. 2022; 10(10).

PMID: 36289774 PMC: 9599207. DOI: 10.3390/biomedicines10102512.

References

Chiba T, Kita K, Zheng Y, Yokosuka O, Saisho H, Iwama A . Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006; 44(1):240-51. DOI: 10.1002/hep.21227. View

Otsuki T, Fujimoto D, Hirono Y, Goi T, Yamaguchi A . Thrombin conducts epithelial‑mesenchymal transition via protease‑activated receptor‑1 in human gastric cancer. Int J Oncol. 2014; 45(6):2287-94. DOI: 10.3892/ijo.2014.2651. View

Pan D . Hippo signaling in organ size control. Genes Dev. 2007; 21(8):886-97. DOI: 10.1101/gad.1536007. View

Wang J, Guo L, Chen L, Zeng Y, Lu S . Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007; 67(8):3716-24. DOI: 10.1158/0008-5472.CAN-06-4343. View

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View

Zhao B, Wei X, Li W, Udan R, Yang Q, Kim J . Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21):2747-61. PMC: 2045129. DOI: 10.1101/gad.1602907. View

Camargo F, Gokhale S, Johnnidis J, Fu D, Bell G, Jaenisch R . YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007; 17(23):2054-60. DOI: 10.1016/j.cub.2007.10.039. View

Lei Q, Zhang H, Zhao B, Zha Z, Bai F, Pei X . TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008; 28(7):2426-36. PMC: 2268418. DOI: 10.1128/MCB.01874-07. View

Chan S, Lim C, Guo K, Peng Ng C, Lee I, Hunziker W . A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68(8):2592-8. DOI: 10.1158/0008-5472.CAN-07-2696. View

10.

Chambers R, Leoni P, Wembridge D, Laurent G . Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem. 2000; 275(45):35584-91. DOI: 10.1074/jbc.M003188200. View

11.

Griffin C, Srinivasan Y, Zheng Y, Huang W, Coughlin S . A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001; 293(5535):1666-70. DOI: 10.1126/science.1061259. View

12.

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

13.

Goodell M, Brose K, Paradis G, Conner A, Mulligan R . Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183(4):1797-806. PMC: 2192511. DOI: 10.1084/jem.183.4.1797. View

14.

Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, GINZBURG Y, Reich R . Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998; 4(8):909-14. DOI: 10.1038/nm0898-909. View

15.

Chan E, Nousiainen M, Chalamalasetty R, Schafer A, Nigg E, Sillje H . The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005; 24(12):2076-86. DOI: 10.1038/sj.onc.1208445. View

16.

Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M . Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005; 36(6):676-85. DOI: 10.1016/j.humpath.2005.04.008. View

17.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang D . Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005; 65(14):6207-19. DOI: 10.1158/0008-5472.CAN-05-0592. View

18.

Chen J, Hersmus N, Van Duppen V, Caesens P, Denef C, Vankelecom H . The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology. 2005; 146(9):3985-98. DOI: 10.1210/en.2005-0185. View

19.

Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A . Cancer stem cells in human gastrointestinal cancers. Hum Cell. 2006; 19(1):24-9. DOI: 10.1111/j.1749-0774.2005.00004.x. View

20.

Zhao B, Ye X, Yu J, Li L, Li W, Li S . TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22(14):1962-71. PMC: 2492741. DOI: 10.1101/gad.1664408. View